• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在嵌合抗原受体T细胞疗法后,一名复发/难治性多发性骨髓瘤患者未进行预处理方案的成功单倍体相合移植。

A successful haploidentical transplantation without conditioning regimen for a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T-cell therapy.

作者信息

Dai Zigang, Yu Nanzhou, Cao Yang, Zhou Jianfeng, Zhang Yicheng, Wang Na, Zhou Xiaoxi

机构信息

Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.

Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.

出版信息

Cytotherapy. 2025 Mar;27(3):295-299. doi: 10.1016/j.jcyt.2024.10.005. Epub 2024 Dec 16.

DOI:10.1016/j.jcyt.2024.10.005
PMID:39729053
Abstract

BACKGROUND AIMS

With novel therapies improving prognosis, the complications of multiple myeloma after multi-line treatment, particularly myelosuppression, have become a crucial determinant of long-term outcomes. Non-myeloablative allogeneic hematopoietic stem cell transplantation is a feasible option, but the transplant-related mortality rate remains high. Our study presents a relapsed/refractory multiple myeloma patient with a 9-year disease history.

METHODS

The patient underwent multiple chemotherapy treatments and achieved partial remission. The patient then received two B-cell maturation antigen-targeting chimeric antigen receptor (CAR) T-cell treatments with lymphodepletion conditioning of fludarabine and cyclophosphamide.

RESULTS

At the fifth month after the second CAR T-cell treatment, the patient achieved complete remission but developed refractory myelosuppression (grade 4 according to Common Terminology Criteria for Adverse Events 5.0) after several severe infections. In order to facilitate hematopoietic recovery, her daughter's stem cells were infused into her, which fortunately implanted without conditioning. After thrombotic microangiopathy and acute graft-versus-host disease, the patient was discharged with consistent full donor chimerism. We assume this engraftment may be attributed to the patient's severe hematopoietic failure and further host lymphodepletion by fludarabine.

CONCLUSIONS

This study highlights the potential of allogeneic hematopoietic stem cell transplantation with reduced conditioning intensity or even the omission of conditioning, particularly for a relapsed/refractory multiple myeloma patient who struggles with severe myelosuppression after long-term treatment.

摘要

背景与目的

随着新型疗法改善预后,多线治疗后多发性骨髓瘤的并发症,尤其是骨髓抑制,已成为长期预后的关键决定因素。非清髓性异基因造血干细胞移植是一种可行的选择,但移植相关死亡率仍然很高。我们的研究介绍了一位有9年病史的复发/难治性多发性骨髓瘤患者。

方法

该患者接受了多次化疗并达到部分缓解。随后,患者接受了两次靶向B细胞成熟抗原的嵌合抗原受体(CAR)T细胞治疗,并采用氟达拉滨和环磷酰胺进行淋巴细胞清除预处理。

结果

在第二次CAR T细胞治疗后的第五个月,患者达到完全缓解,但在经历几次严重感染后出现难治性骨髓抑制(根据不良事件通用术语标准5.0为4级)。为促进造血恢复,将其女儿的干细胞输注给她,幸运的是,未进行预处理干细胞就成功植入。在出现血栓性微血管病和急性移植物抗宿主病后,患者出院时供体嵌合率持续完全。我们认为这种植入可能归因于患者严重的造血功能衰竭以及氟达拉滨进一步导致的宿主淋巴细胞清除。

结论

本研究强调了降低预处理强度甚至省略预处理的异基因造血干细胞移植的潜力,特别是对于长期治疗后出现严重骨髓抑制的复发/难治性多发性骨髓瘤患者。

相似文献

1
A successful haploidentical transplantation without conditioning regimen for a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T-cell therapy.在嵌合抗原受体T细胞疗法后,一名复发/难治性多发性骨髓瘤患者未进行预处理方案的成功单倍体相合移植。
Cytotherapy. 2025 Mar;27(3):295-299. doi: 10.1016/j.jcyt.2024.10.005. Epub 2024 Dec 16.
2
Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature.来那度胺增强抗 BCMA CAR-T 治疗复发/难治性多发性骨髓瘤的疗效:一例病例报告及文献复习。
Cancer Immunol Immunother. 2022 Jan;71(1):39-44. doi: 10.1007/s00262-021-02959-8. Epub 2021 May 18.
3
Donor-derived CAR-T Cells Serve as a Reduced-intensity Conditioning Regimen for Haploidentical Stem Cell Transplantation in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Case Report and Review of the Literature.供体来源的 CAR-T 细胞作为减轻强度预处理方案,用于治疗复发/难治性急性淋巴细胞白血病的单倍体相合干细胞移植:病例报告及文献复习。
J Immunother. 2018 Jul/Aug;41(6):306-311. doi: 10.1097/CJI.0000000000000233.
4
Case report: Donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission.病例报告:供体衍生的慢性淋巴细胞白血病嵌合抗原受体 T 细胞治疗缓解后复发/难治性急性髓系白血病桥接异基因造血干细胞移植。
Front Immunol. 2024 May 13;15:1389227. doi: 10.3389/fimmu.2024.1389227. eCollection 2024.
5
Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.使用白消安、氟达拉滨和抗胸腺细胞球蛋白进行减低强度预处理用于缓解期急性髓系白血病患者接受无关或单倍体相合家庭供者造血细胞移植
Biol Blood Marrow Transplant. 2017 Sep;23(9):1555-1566. doi: 10.1016/j.bbmt.2017.05.025. Epub 2017 May 25.
6
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.经基因修饰表达抗 B 细胞成熟抗原嵌合抗原受体的 T 细胞可引起预后不良的复发性多发性骨髓瘤缓解。
J Clin Oncol. 2018 Aug 1;36(22):2267-2280. doi: 10.1200/JCO.2018.77.8084. Epub 2018 May 29.
7
Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.对晚期血液系统恶性肿瘤患者进行非清髓性预处理的异基因造血细胞移植。
Cytotherapy. 2001;3(4):253-60. doi: 10.1080/146532401317070880.
8
Case Report: Unedited allogeneic chimeric antigen receptor T cell bridging to conditioning-free hematopoietic stem cell transplantation for a child with refractory Burkitt lymphoma.病例报告:未编辑的同种异体嵌合抗原受体 T 细胞桥接无预处理造血干细胞移植治疗难治性伯基特淋巴瘤患儿。
Front Immunol. 2023 Sep 6;14:1219872. doi: 10.3389/fimmu.2023.1219872. eCollection 2023.
9
Prognostic differences between carmustine, etoposide, cytarabine and melphalan (BEAM) and carmustine, etoposide, cytarabine, melphalan and fludarabine (BEAMF) regimens before autologous stem cell transplantation plus chimeric antigen receptor T therapy in patients with refractory/relapsed B-cell non-Hodgkin-lymphoma.难治性/复发性B细胞非霍奇金淋巴瘤患者在自体干细胞移植加嵌合抗原受体T细胞治疗前,卡莫司汀、依托泊苷、阿糖胞苷和美法仑(BEAM)方案与卡莫司汀、依托泊苷、阿糖胞苷、美法仑和氟达拉滨(BEAMF)方案的预后差异。
Cytotherapy. 2024 May;26(5):456-465. doi: 10.1016/j.jcyt.2024.01.012. Epub 2024 Feb 19.
10
Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens.三种不同预处理方案用于多发性骨髓瘤异基因造血细胞移植结局的比较。
Biol Blood Marrow Transplant. 2019 May;25(5):1039-1044. doi: 10.1016/j.bbmt.2019.01.009. Epub 2019 Jan 11.